VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 24, 2006) - WEX Pharmaceuticals Inc. (the “Company”) (TSX:WXI) is pleased to announce that a pre-CTA (Clinical Trial Applications) meeting has been scheduled with the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada on the 5th of September in Ottawa. The purpose of this meeting is to present the results of the new data analysis of the double-blind study (WEX-014) and the long term safety and efficacy study of TectinTM (WEX-014OL) in cancer-related pain. The Company will also discuss the future development of TectinTM with the BGTD.
